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Background:	 	 Chronic	 Obstructive	 Pulmonary	 Disease	 (COPD)	 is	 a	 complex,	 progressive	
respiratory	condition.	There	is	growing	evidence	that	people	with	COPD	may	experience	some	
degree	 of	 cognitive	 dysfunction.	 Most	 COPD	 patients	 maintain	 relatively	 long	 periods	 of	
stable	health.	Despite	this,	previous	reviews	on	this	topic	have	included	both	exacerbating	
and	stable	samples	and	investigations	have	been	limited	to	examine	only	general	cognitive	






narrative	 review.	 All	 studies	 were	 quality	 rated	 using	 a	 protocol	 developed	 from	 SIGN	
Methodology	Checklist	4.		
Results:		Stable	COPD	patients	consistently	attained	significantly	lower	scores	than	controls	
across	 several	 cognitive	domains,	 including	processing	speed,	memory,	concept	 formation	
and	abstract	reasoning,	and	executive	functions.		
Conclusions:	COPD	patients	may	be	at	 risk	of	experiencing	cognitive	difficulties,	even	 in	a	










al.,	 2016)	 and	 is	 largely	 associated	with	 chronic	 exposure	 to	 environmental	 pollutants	 or	
smoking	 (Global	 Initiative	 for	 Chronic	 Obstructive	 Lung	 Disease	 (GOLD),	 2016).	 Primary	






Comorbidities	 are	 common	 in	 COPD	 patients.	 Secondary	 cardiovascular	 problems	 are	
frequently	observed	(Barnes	and	Celli,	2009)	alongside	conditions	such	as	diabetes	(Feary	et	
al.,	 2010);	 cancer	 (Anthonisen	 et	 al.,	 2002);	 sleep	 apnoea	 (McNicholas,	 2016)	 and	mood	
disorders	 (Hynninen	 et	 al.,	 2005).	 Given	 such	 circumstances,	 clinicians	 are	 increasingly	
recognising	the	necessity	of	whole-patient	approaches,	incorporating	routine	screening	and	
clinical	management	considerations	for	all	relevant	comorbidities	(Dodd,	Getov	and	Jones,	
2010).	 In	 line	with	 these	developments,	 recent	attention	has	been	given	 to	 the	anecdotal	
accounts	 of	 memory	 problems	 and	 “brain	 fog”	 which	 are	 commonly	 reported	 by	 COPD	
patients.	Indeed,	given	that	primary	disease	presentation	directly	influences	circulating	blood	
gases,	it	may	be	reasonable	to	expect	that	some	damage	or	dysfunction	to	oxygen-sensitive	
brain	 regions	 could	 arise	 in	 this	 condition	 (Paola	 et	 al.,	 2008).	 Several	 recent	
neuropsychological	 literature	 reviews	 have	 explored	 the	 relationship	 between	 COPD	 and	







The	pathology	underlying	 cognitive	dysfunction	 in	COPD	 is	 complex	and,	 to	date,	 remains	
unclear.	Several	authors	have	endeavoured	 to	 identify	 the	potential	mechanisms	 involved	
(Borson	 et	 al.,	 2008;	 Dodd,	 Getov	 and	 Jones,	 2010;	 Cleutjens	 et	 al.,	 2014).	 While	 some	
associations	between	cognitive	abilities	and	disease	severity	have	been	found	(Schou	et	al.,	
2012),	 there	 is	mounting	 literature	 addressing	 the	 role	 of	 circulating	 blood-gases.	 Several	
papers	have	demonstrated	a	 relationship	between	hypoxemia	 (abnormally	 low	circulating	
oxygen	levels),	and	to	a	lesser	extent	hypercapnia	(abnormally	high	circulating	carbon	dioxide	








stability	 and	 prevention	 of	 exacerbations:	 “acute	 events	 characterised	 by	 a	 worsening	 of	
symptoms	 beyond	 normal	 day-to-day	 variations”(GOLD,	 2016).	 Exacerbations	 commonly	











cognitive	 difficulties	 arising	 in	 COPD.	 Evidence	 from	 other	 chronic	 health	 conditions	 has	
demonstrated	relationships	between	cognitive	dysfunction	and	a	range	of	clinical	outcomes.		
Difficulties	with	disease	management	and	medication	adherence	has	been	associated	with	
cognitive	problems	 in	heart	 failure	and	diabetes	 (Alosco	et	al.,	2012;	Hopkins,	Shaver	and	
Weinstock,	 2016).	 Additionally	 cognitive	 difficulties	 have	 been	 linked	 to	 reductions	 in	
activities	of	daily	living	in	chronic	kidney	disease	(Goto,	2017)	and	quality	of	life	in	multiple	
sclerosis	 (Benito-Leon,	 Morales	 and	 Rivera-Navarro,	 2002).	 In	 the	 current	 healthcare	
landscape	of	increasing	emphasis	on	self-management,	it	is	important	that	considerations	of	
cognitive	difficulties	are	incorporated	into	treatment	guidelines.		Neglecting	to	acknowledge	


















and	methodology	 (Hynninen	et	al.,	 2005;	Schou	et	al.,	 2012;	Torres-Sánchez	et	al.,	 2015).	
Many	 have	 taken	 an	 inclusive	 approach	 to	 study	 selection	 with	 regards	 to	 sample	
characteristics.	Included	samples	have	originated	from	a	wide	variety	of	sources	with	many	
recruiting	via	inpatient	respiratory	services.	As	such,	a	large	proportion	of	participants	were	
exacerbating	 COPD	 patients.	 While	 insights	 into	 cognitive	 function	 during	 exacerbation	
contribute	to	the	overall	picture	of	this	condition,	exacerbation	phases	tend	to	cover	brief	
periods	in	the	lifecycle	of	the	disease.	Furthermore,	self-management	abilities	are	likely	to	
have	more	 impact	 upon	 outcomes	 in	 a	 stable	 phase,	 thus	 knowledge	 regarding	 cognitive	
function	 during	 exacerbation	 is	 limited	 in	 its	 clinical	 utility.	 	 Finally,	 undifferentiated	
assessment	 of	 stable	 and	 exacerbating	 patients	 introduces	 a	 meaningful	 confound,	 thus	
reducing	 the	 strength	 of	 conclusions	 drawn.	 Therefore,	 this	 review	 aims	 to	 examine	 the	
literature	investigating	cognitive	function	in	stable	COPD	and	address	the	following	questions:	
(1)	What	 is	 the	nature	of	cognitive	dysfunction	 in	stable	COPD?	 (2)	 Is	 there	a	 relationship	
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The	 search	 strategy	was	 customised	 for	 each	 database	 and	 utilised	 controlled	 vocabulary	
(MeSH)	and	keywords.	The	following	databases	were	systematically	searched:	Medline	(via	
Ovid	Medline	(R)	1946	to	week	1	January	2018	and	OVID	Medline	(R)	in-process	and	other	






1. Chronic	 Obstructive	 Pulmonary	 Diseas*	 OR	 copd	 OR	 Pulmonary	 Disease,	 Chronic	
Obstructive	(MeSH)		
2. Cognitive	OR	Cognition	OR	Cognition	disorders	(MeSH)	OR	Cognitive	defect	 (MesH)	









diagnosis	 of	 COPD	 which	 is	 classified	 as	 stable,	 (vi)	 study	 provides	 a	 neuropsychological	
measure	 of	 function	 in	 a	 specific	 cognitive	 domain(s).	 Studies	 that	 reported	 only	 general	
cognitive	ability,	 for	example	 total	Montreal	Cognitive	Assessment	 scores,	were	excluded.			




Study	 quality	 was	 examined	 using	 an	 adapted	 version	 of	 the	 Scottish	 Intercollegiate	
Guidelines	Network	(SIGN)	Methodology	Checklist-4:	Case-control	studies	(2008)	[Appendix	
1.2].	This	protocol	consists	of	nine	items	covering	five	methodological	issues:	study	question,	
subject	 selection,	 assessment,	 confounding	 factors	 and	 statistical	 analysis.	 Each	 item	was	
















and	 control	 groups	were	explored.	However,	 the	 studies	 included	 in	 this	 review	varied	 in	



























demographic-predicted	 FEV1(FEV1%pred.).	 Prior	 to	 2011,	GOLD	promoted	 the	 adoption	of	












recently	 revised	 guidelines	 introduced	 the	 inclusion	 of	 self-reported	 symptoms	 and	
exacerbation	history	into	severity	gradings	(GOLD,	2016).	Only	one	study	in	this	review		
reported	 severity	 in	 this	 manner	 (Karakontaki	 et	 al.,	 2013).	 Further	 details	 of	 GOLD	
classification	 systems	 are	 illustrated	 in	 Appendix	 1.4.	 	 The	 overall	 range	 of	 severity	 of	



























articles	ensured	 that	 cases	and	 controls	 came	 from	comparable	populations	 (Grant	et	al.,	
1982;	Incalzi	et	al.,	1997;	Liesker	et	al.,	2004;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	2017)	and	six	
ensured	controls	were	non-cases	(Grant	et	al.,	1982;	Ortapamuk	and	Naldoken,	2006;	Dodd	
et	 al.,	 2013;	 Ryu	 et	 al.,	 2013;	 Cleutjens	 et	 al.,	 2017;	 Spilling	 et	 al.,	 2017).	 Seven	 studies	





































































































































































































































































































































































































































































































































































































































































	 X	 	 	 	 	 	 X	 	 	
Cleutjens	(2017)	
	 X	 X	 	 	 	 	 X	 	 X	
Dodd	(2013)	
	 X	 X	 	 	 X	 	 X	 	 X	
Grant	(1982)	
	 	 	 	 X	 X	 X	 X	 X	 X	
Incalzi	(1997)	
	 	 X	 	 	 	 	 X	 	 	
Karakontaki	(2013)	
	 X	 	 	 X	 	 	 	 	 	
Liesker	(2004)	
	 X	 	 	 	 	 	 	 X	 X	
Ortapamuk	(2006)	
	 	 X	 	 	 	 	 X	 	 	
Ryu	(2013)	
	 	 	 	 	 	 	 	 X	 X	
Spilling	(2017)	
	 X	 X	 	 	 	 	 X	 	 X	









attained	 significantly	 lower	 scores	 than	 controls	 in	 every	 study	 examining	 processing	 speed	
(Liesker	et	al.,	2004;	Borson	et	al.,	2008;	Dodd	et	al.,	2013;	Karakontaki	et	al.,	2013;	Cleutjens	et	
al.,	2017;	Spilling	et	al.,	2017),	but	only	 in	half	of	 the	 investigations	of	attention	and	working	
memory	(Incalzi	et	al.,	1997;	Ortapamuk	and	Naldoken,	2006;	Dodd	et	al.,	2013;	Cleutjens	et	al.,	
2017;	Spilling	et	al.,	2017).	No	significant	between-group	differences	were	 identified	 in	either	









Eight	out	of	 ten	papers	assessing	memory	performance	observed	 that	 the	COPD	group	mean	
scores	were	significantly	 lower	than	the	control	group	(Grant	et	al.,	1982;	 Incalzi	et	al.,	1997;	
Ortapamuk	 and	 Naldoken,	 2006;	 Borson	 et	 al.,	 2008;	 Zhang	 et	 al.,	 2012;	 Dodd	 et	 al.,	 2013;	
	 28	
Cleutjens	et	al.,	2017;	Spilling	et	al.,	2017).	Distinctions	were	made	between	verbal	and	non-
verbal	 memory	 in	 many	 of	 these	 studies,	 with	 three	 (Incalzi	 et	 al.,	 1997;	 Ortapamuk	 and	
Naldoken,	2006;	Borson	et	al.,	 2008)	and	 two	articles	 (Grant	et	al.,	 1982;	Zhang	et	al.,	 2012)	
illustrating	 significantly	 lower	 scores	 for	 COPD	participants	 in	 verbal	 and	 non-verbal	memory	
tasks	in	comparison	to	controls.	Interestingly,	Incalzi	et	al.	(1997)	compared	the	verbal	memory	
profile	of	COPD	patients	with	aged-matched	healthy,	Alzheimer’s	and	older	healthy	participants.		
This	 analysis	 highlighted	 reduced	 retrieval	 efficiency	 in	 comparison	 to	 age-matched	 controls.	
However,	COPD	patients’	memory	scores	were	significantly	better	than	the	Alzheimer’s	group.		
















functional	 impact	 of	 any	 cognitive	 difficulties	 in	 this	 disease,	 it	 is	 necessary	 to	 examine	 the	
magnitude	cognitive	difficulties	observed	in	COPD	groups,	either	in	comparison	to	control	groups	
or	 standardised	 norms.	 A	 few	 included	 studies	 made	 some	 investigation	 of	 the	 severity	 of	
cognitive	difficulties.	 	Cleutjens	et	al.	 (2017)	examined	compound	z-scores	across	functions	of	
processing	 speed,	 planning,	 working	memory,	 verbal	memory	 and	 cognitive	 flexibility.	While	
COPD	 patients	 performed	 significantly	 worse	 than	 controls	 on	 these	 measures,	 only	 their	
cognitive	 flexibility	 performance	 reached	 levels	 of	 clinical	 impairment	 (Z-score	 below	 -1SD).	
Another	study	reported	the	proportion	of	different	groups	to	meet	classifications	for	‘moderate	
to	severe’	impairment	(Dodd	et	al.,	2013).	A	substantial	proportion	(>20%)	of	the	COPD	group	
fell	 within	 this	 impaired	 range	 (Z-score	 below	 -1SD)	 on	 subtasks	 examining	memory,	mental	
switching,	 processing	 speed	 and	 visuospatial	 function.	 In	 contrast,	 a	 study	 exploring	 driving-
related	attentional	 performance	 reported	percentiles	 for	COPD	participants	 falling	within	 the	



















































































































































































































Overall,	 most	 studies	 examining	 the	 relationship	 between	 arterial	 blood	 gases	 (ABGs)	 and	





executive	 skills	 (Liesker	 et	 al.,	 2004).	 Significant	 correlations	 were	 demonstrated	 between	
neuropsychological	performance	and	partial	pressure	of	oxygen	 in	some	studies	 (Grant	et	al.,	
1982;	Karakontaki	et	al.,	2013).	Although,	circulating	oxygen	levels	did	not	appear	to	correlate	
with	 cognitive	 scores	 in	 a	 group	 of	 non-hypoxemic	 patients,	 despite	 the	 group	 performing	
significantly	poorer	 than	controls	 (Liesker	et	al.,	2004).	The	 impact	of	oxygen	dependence	on	
neuropsychological	 functioning	 was	 unclear	 with	 conflicting	 studies	 reporting	 evidence	 for	
(Borson	et	al.,	2008)	and	against	 (Cleutjens	et	al.,	2017)	 significantly	 reduced	performance	 in	
oxygen-dependent	 patients,	 in	 contrast	 to	 controls.	 The	 relationship	 with	 hypercapnia	 was	
examined	 less	 often	 and	 findings	 are	 unclear.	 Two	 studies	 concluded	PCO2	 levels	made	 little	
difference	to	cognitive	scores	(Grant	et	al.,	1982;	Dodd	et	al.,	2013).	However,	Karakontaki	et	al.,	
(2013)	 identified	 significantly	 longer	 reaction	 times	 in	 hypercapnic	 patients,	 compared	 to	
controls.		
	
Disease	 severity	 seemed	 to	 have	 little	 relationship	 with	 cognitive	 difficulties.	 Two	 studies	
demonstrated	 no	 significant	 association	 between	 overall	 cognitive	 performance	 and	 disease	
	 34	
severity	 (Grant	 et	 al.,	 1982;	 Liesker	 et	 al.,	 2004)	 while	 FEV1(%pred.)	 explained	 only	 modest	
variations	in	Dodd	et	al.	(2013).	However,	one	study	identified	significant	correlations	between	
lung	 function,	 reaction	 times	 and	 visuospatial	 abilities	 (Karakontaki	et	 al.,	 2013).	 Similarly,	 in	





Despite	 the	widely	 evidenced	 influence	 of	mental	 health	 on	 cognitive	 abilities,	many	 studies	
neglected	 this	 potential	 confound.	 For	 example,	 Borson	 et	 al.	 (2008)	 reported	 co-occurring	
significant	differences	in	measures	of	mood	and	cognitive	functioning	yet	did	not	examine	any	
association	 between	 these	 variables.	 In	 a	more	 detailed	 investigation,	 Cleutjens	et	 al.	 (2017)	
reported	 higher	 levels	 of	 anxiety	 and	 depression	 in	 COPD	 participants	 but	 did	 not	 find	 any	
significant	 differences	 in	 cognitive	 performance	 when	 comparing	 COPD	 patients	 above	 and	
below	clinical	thresholds	for	mood.	Similarly,	the	influence	of	smoking	history	was	not	commonly	
addressed.	One	study	suggested	that	smoking	history	may	explain	significant	but	very	modest	












variation,	 it	 is	difficult	 to	 identify	a	particular	“cognitive	profile”	of	stable	COPD.	 	Widespread	
difficulties	 across	 domains	 may	 be	 indicative	 of	 general	 cognitive	 decline	 in	 keeping	 with	
suggested	theories	of	an	accelerated	aging	influence	of	the	disease	(Grant	et	al.,	1982;	Kirkil	et	
al.,	 2007).	 	 Overall,	 significant	 group	 differences	 and	 noteworthy	 effect	 sizes	 were	 most	
consistently	 found	 in	 the	 domains	 of	 processing	 speed,	 concept	 formation	 and	 abstract	
reasoning,	executive	functions	and	memory.	Cognitive	difficulties	seem	to	have	some	association	
with	hypoxemia,	while	hypercapnia	and	disease	severity	appear	to	exert	less	influence.	This	was	
the	 first	 review	 to	 examine	 domain-specific	 cognitive	 abilities	 in	 only	 stable	 COPD	 samples.	






functional	 abilities.	 Incalzi	 et	 al	 (1997)	 reported	 significant	 correlations	 between	medication	











to	 provide	 information	 and	 instructions	 at	 an	 appropriate	 speed,	 in	 small	 chunks.	 	 	Memory	
difficulties	 may	 influence	 ability	 to	 recall	 treatment	 schedules	 or	 educational	 information.	




exacerbations	 (Hall	 and	 Marteau,	 2014).	 Support	 for	 self-monitoring	 and	 decision-making,	










of	 “stable”	was	 accepted	 after	 one	week	of	 unchanged	ABGs.	 The	 remaining	 articles	 did	 not	






Quality	 inspection	 of	 reviewed	 studies	 also	 raises	 some	 concerns	 around	 fulfilment	 of	
appropriate	sample	sizes.	Only	three	studies	referenced	power	calculations	to	justify	sample	sizes	






include	skewed	data	 (Liesker	et	al.,	2004).	 It	was	not	possible	 to	calculate	the	effect	sizes	 for	





and	 interpretation	 applied	 in	 these	 studies.	 	 Some	 of	 the	 included	 studies	 were	 medically	
oriented,	examining	cognitive	performance	as	a	secondary	outcome	of	interest.	Consequently,	
application	of	neuropsychological	theory	in	these	studies	was	limited.	In	addition,	it	is	important	
to	acknowledge	 that	no	 singular	aspect	of	 cognition	can	be	examined	 in	 isolation.	Therefore,	
performance	on	any	task	thought	to	examine	a	specific	cognitive	function	will	also	be	influenced	
to	 varying	 degrees	 by	 additional	 domains.	 	 A	 wide	 range	 of	 assessment	 measures	 were	
implemented	 across	 included	 studies	 each	 varying	 in	 psychometric	 properties.	 Furthermore,	
adequate	descriptions	or	references	for	these	tests	were	lacking	in	several	studies,	substantially	
reducing	replicability	and	critical	interpretation.	A	range	of	different	scoring	methods	were	also	
implemented	 including	 raw	 and	 scaled	 individual	 subtest	 scores,	 and	 domain-specific	 index	












identification	 of	 at-risk	 patients.	 Better	 awareness	 of	 such	 issues	 may	 lead	 to	 targeted	
intervention	studies	to	assess	effectiveness	of	cognitive	rehabilitation	or	assistive	technology	in	
identified	 patient	 groups.	 Although,	 in	 order	 to	 ensure	 validity	 of	 conclusions,	 careful	
consideration	should	be	given	to	the	application	of	neuropsychological	theory	in	this	medically	
driven	 field.	The	 findings	of	 this	 review	promote	 the	potential	benefits	of	neuropsychological	
assessment	 in	 routine	 COPD	 care.	 However,	 assessment	 using	 comprehensive	














































































































































































































Background:	 Chronic	 Obstructive	 Pulmonary	 Disease	 (COPD)	 is	 an	 umbrella	 term	 for	 several	
conditions	 causing	 progressive	 and	 irreversible	 damage	 to	 the	 airways.	 There	 is	 evidence	 to	





and	how	 long	we	can	concentrate	on	something.	Klein	et	al’s	previous	study	used	a	 tool,	 the	

















whether	a	warning	cue	was	presented	or	not.	Orienting	 is	“the	selection	of	 information	 from	
sensory	 input”	and	was	 investigated	by	examining	 reaction	 times	when	 the	warning	 cue	was	
presented	 in	 different	 locations.	 Response	 inhibition	 involves	 “resolving	 conflict	 among	
responses,	overcoming	a	strong	automatic	response”.	This	aspect	of	attention	was	measured	by	
presenting	 the	 target	 arrow,	 to	which	 the	 participant	was	 to	 respond,	 accompanied	 by	 four	
flanking	arrows.	Response	inhibition	was	measured	by	comparing	reactions	times	for	when	the	
flanking	arrows	were	pointing	in	the	same	or	different	direction	as	the	target	arrow.	Two	other	







Results:	 The	 people	 with	 stable	 COPD	 who	 were	 included	 in	 this	 study	 had	 more	 difficulty	
maintaining	 alertness	 (alerting)	 and	 suppressing	 a	 natural	 and	 automatic	 response	 (response	



































three	 attention-based	 tasks:	 Attention	 Network	 Test,	 Stroop	 Colour-Word	 Task	 and	 Hayling	



















(GOLD),	 2016).	 Airflow	 limitation	 to	 the	 lungs,	 causing	 breathlessness,	 typically	 results	 from	
inflammatory	responses	to	noxious	environmental	particles	or	smoking.	However,	the	impact	of	




One	 thread	 of	 investigation	 has	 identified	 increasing	 evidence	 that	 people	 with	 COPD	 may	
experience	some	degree	of	cognitive	dysfunction	(Hynninen	et	al.,	2005;	Dodd,	Getov	and	Jones,	












nature	 of	 the	 condition.	 Several	 studies	 have	 explored	 the	 pathology	 underlying	 this	 issue	










(Schou	et	al.,	 2012).	 Interpretation	of	 these	 findings	 is	 complicated	by	 short-term	changes	 in	
symptoms.		Although	most	COPD	patients	maintain	long	periods	of	a	relatively	stable	condition,	









influence	 on	 cognitive	 function.	 To	 adequately	 examine	 brain	 function	 in	 this	 condition	 it	 is	
important	 to	 include	 consideration	 of	 these	 disease-related	 variables	 and	 comorbidities	 into	
research	design.		
	
Given	 the	 complex	 pathology	 of	 this	 disease	 is	 dominated	 by	 reduced	 circulating	 oxygen,	
cognitive	 impairment	 may	 be	 expected	 to	 arise	 through	 damage	 or	 dysfunction	 of	 oxygen-
sensitive	neuroanatomical	regions,	namely	the	hippocampus,	basal	ganglia	and	frontal	cerebral	




et	 al.,	 2003;	 Dodd	 et	 al.,	 2015;	 Cleutjens	 et	 al.,	 2017;	 Spilling	 et	 al.,	 2017).	 However,	 many	
medically-oriented	studies	reporting	on	cognitive	 function	have	examined	this	as	a	secondary	
outcome	 of	 interest.	 These	 investigations	 have	 lacked	 a	 theoretically	 driven	 approach	 to	
neuropsychological	investigation	and	findings	have	often	been	inappropriately	generalised.		
	
In	an	 investigation	of	COPD	 inpatients,	Klein	et	al.	 (2009)	utilised	 the	Attention	Network	Test	
(ANT)	 (Fan	 et	 al.,	 2002)	 to	 examine	 functioning	 of	 distinct	 attention	 systems	 proposed	 by	
Peterson	and	Posner	(1990,	2012).	Neuropsychological	definitions	of	attention	vary;	however,	
this	function	is	broadly	viewed	as	the	processing	of	information	or	stimuli	from	the	environment	












Klein	et	al's	 (2009)	 study	 limited	 recruitment	of	COPD	participants	 to	 individuals	 admitted	 to	
hospital	 during	 exacerbation.	 All	 task	 procedures	 were	 completed	 during	 the	 inpatient	 stay,	
when	patients	were	medically	unstable.	Such	sample	selection	introduces	multiple	physiological	
confounds	 which	 may	 have	 influenced	 cognitive	 performance.	 Furthermore,	 the	 conclusions	











1. Performance	 on	 attention	 tasks	 will	 be	 significantly	 reduced	 in	 COPD	 patients,	 in	
comparison	to	controls.		
a. On	 the	 attention	 network	 test,	 COPD	 patients	 will	 show	 significantly	 reduced	
alerting	 and	 orienting	 effects	 in	 comparison	 to	 controls	 and	 will	 experience	 a	



















Forth	Valley,	 during	 attendance	 at	 pulmonary	 rehabilitation	 or	 routine	 review	 appointments.		
Inclusion	 criteria	 for	COPD	participants	were:	 (i)	 a	diagnosis	of	COPD,	 (ii)	 COPD	 is	 considered	
clinically	stable	in	accordance	with	GOLD	(2016)	guidelines	(i.e.	exacerbation-free	for	6	weeks).		
Twenty-three	 control	 participants	 were	 recruited	 as	 a	 convenience	 sample	 from	 the	 local	
community.	 	 All	 participants	were	 one-to-one	matched	 for	 age	 and,	where	 possible,	 gender.		
Exclusion	 criteria	 for	 all	 participants	 were:	 (i)	 history	 of	 neurological	 illness	 or	 event	 (e.g.	
dementia,	 multiple	 sclerosis,	 stroke);	 (ii)	 significant	 sensory	 impairment	 or	 co-morbid	 health	


























NHS	 clinic	 room	 or	 as	 a	 home	 visit.	 Prior	 to	 participation,	 all	 participants	 provided	 written	
informed	consent,	including	granting	access	to	most	recent	spirometry	results	for	COPD	patients	




Demographic	 information	was	 collected	 for	 all	 participants	 (gender,	 age,	 education,	 smoking	
history	and	health	information).	Additionally,	COPD	participants	provided	information	on	years	
of	 illness	 and	 current	 treatment.	 COPD	 patients	 also	 provided	 ratings	 of	 breathlessness	 and	
impact	 on	 function	 on	 a	 commonly	 used	 self-report	measure,	 the	Medical	 Research	 Council	
(MRC)	 Breathlessness	 Scale	 (Fletcher,	 1960)	 [Appendix	 2.12].	 Subsequently	 all	 participants	
completed	the	Hospital	Anxiety	and	Depression	Scale	(HADS)	(Zigmond	and	Snaith,	1983).	This	







The	 ANT	 is	 a	 computer-based	 choice	 reaction	 time	 (RT)	 task	 developed	 to	 examine	 phasic	
alertness,	 spatial	 selective	attention	and	 response	 inhibition.	Through	pressing	corresponding	
buttons	on	a	computer	keyboard,	participants	were	required	to	indicate	whether	a	central	arrow,	
presented	on	a	screen,	pointed	left	or	right.		The	stimuli	(one	central	arrow	or	one	central	arrow	
















inhibition.	 It	 is	 commonly	 used	 in	 neuropsychological	 evaluation	 and	 is	 composed	 of	 two	
sections.	The	first	section	asks	the	participant	to	complete	a	series	of	sentences	with	a	sensible,	
meaningful	word.	The	participant	is	then	required	to	complete	a	second	series	of	sentences	with	















raw	 score.	An	 interference	 scores	 is	 calculated	by	 subtracting	a	predicted	 colour-word	 score,	
based	on	performance	in	the	first	two	sections,	from	the	observed	colour-word	score.		The	SCWT	







exclude	 invalid	 or	 outlier	 trials,	 further	 details	 are	 available	 in	 Appendix	 2.16.	 	 To	 compare	






above	 control	mean;	ANT	alerting	and	orienting	mild	 (>1SD),	moderate	 (>2SD)	below	control	





































































































































participants	 generally	 performed	 poorer	 on	 most	 measures	 of	 attention,	 none	 of	 these	























































Time	2	SSa	 6.13	±	0.55	 6.17	±	0.78	 0.828	 -0.06	
(-0.64	to	0.52)	
	
Converted	Errors	SSb	 6	[2-8]	 7	[6	-	7]	 0.360	 -0.27	
























	 	 	 	 	




								No	cue	(ms)	 785.9	±	98.9	 780.2	±	89.2	 	 	
								Double	cue	(ms)	 764.2	±106.3	 739.6	±	89.8		 	 	
	 	 	 	 	




							Centre	cue	(ms)	 771.7	±	96.2	 763.1	±	93.0	 	 	
							Spatial	cue	(ms)	 728.7	±	110.0	 714.6±	80.4	 	 	
	 	 	 	 	
Relative	Conflictb		 21.0	[17.8	–	24.5]	 19.6	[17.4	–	23.8]	 0.448	 -0.22	
	
							Incongruent	(ms)	 897	[851	–	1014]	 874	[811	–	967]	 	 	

























1(4.3)	 0	(0.0)	 1.000†	 0.000	




0(0.0)	 1(4.3)	 1.000†	 0.000	















































































Table	 4	 provides	 a	 summary	 of	 exploratory	 correlational	 analyses	 examining	 relationships	
between	 participant	 characteristics	 and	 attention	 measure	 performance.	 Few	 significant	
correlations	 were	 observed.	 However,	 age	 (r	 =	 0.453,	 p	 =0.03)	 and	 self-reported	 levels	 of	





















































































































































































































































































































































































































































































groups	performed	poorer	 than	controls,	processing	speed	 in	 the	exacerbating	participants	
was	significantly	slower	than	the	stable	group.	This	prospective	investigation	also	observed	
some	 improvement	 of	 these	 difficulties	 three	 months	 after	 exacerbation.	 Nevertheless,	
processing	speed	difficulties	in	stable	cohorts	have	been	reported	previously	(Liesker	et	al.,	









stable	 patients	 may	 make	 less	 errors	 than	 exacerbating	 counterparts	 on	 simple	 visual	








Klein	et	al.	 (2009).	Such	similar	 findings	would	suggest	 that	COPD	patients,	 in	any	disease	
phase,	may	be	less	vigilant	than	their	peers	and	gain	less	benefit	from	alarm	cues.	In	contrast,	
the	current	study’s	selective	attention	(orienting)	results,	assessed	by	the	spatial	orienting	
effect,	 differ	 from	 those	 of	 Klein	 et	 al.	 (2009).	While	 this	 study	 of	 exacerbating	 patients	
demonstrated	a	 small	 to	medium	negative	effect	 size,	 the	 current	 investigation	 identified	
little	between-group	difference.	Equivalent	proportions	of	each	group	were	deemed	as	mildly	
impaired	on	this	subtask	and,	while	performance	of	one	COPD	participant	was	suggestive	of	
moderate	 impairment,	 it	 is	 unclear	 whether	 this	 result	 is	 clinically	meaningful.	 Relatively	





to	 examine	 response	 inhibition.	 Firstly,	 the	 substantial	 variability	 observed	 in	 individual	
	 72	
participant’s	conflict	effects	should	be	noted.	The	distribution	of	these	scores,	particularly	for	
the	COPD	group,	 necessitated	non-parametric	 analyses.	Nevertheless,	 consistent	with	 the	




patterns	 were	 also	 observed	 in	 the	 HSCT	 with	 response	 inhibition	 errors	 indicating	
impairment	 in	 several	 participants	 across	 both	 groups,	 although	 impairment	 was	 slightly	
more	common	in	the	COPD	group	(34.8%	vs	21.7%).	Given	the	demographic	characteristics	









stable	COPD	groups	have	been	mixed.	While	 Cleutjens	et	 al.	 (2017)	 reported	 significantly	
reduced	performance	 in	COPD	patients,	 in	comparison	to	controls,	a	similar	 study	did	not	
support	these	findings	(Pereira	et	al.,	2011).	Notably,	both	Liesker	et	al.	(2004)	and	Ryu	et	al.	
(2013)	identified	significantly	diminished	performance	only	in	a	sub-group	of	participants	with	
severe	 COPD.	 No	 difficulties	 were	 reported	 in	 the	 moderate	 group.	 Executive	 attention	
dysfunction	 on	 the	 attentional	 switching	 sub-task	 of	 the	 Trail-making	 test	 has	 also	 been	
	 73	
indicated	 by	 several	 studies	 (Grant	 et	 al.,	 1982;	 Liesker	 et	 al.,	 2004;	 Dodd	 et	 al.,	 2013).	
However,	this	trend	did	not	appear	to	generalise	to	a	more	complex	task	examining	driving-
related	 executive	 abilities	 	 (Karakontaki	et	 al.,	 2013).	 These	 findings,	 taken	 together	with	
those	of	the	current	study,	seem	to	suggest	that	stable	COPD	participants	may	be	at	some	
increased	 risk	 of	 experiencing	 executive	 attention	 difficulties	 and,	 in	 particular,	 a	 small	
proportion	may	experience	impairment	sufficient	to	impact	on	day-to-day	functioning.			
	
However,	 as	 previously	 mentioned,	 care	 is	 required	 when	 interpreting	 SCWT	 results	 in	
respiratory	groups.		Most	studies	utilising	this	measure	examined	response	inhibition	as	the	
number	of	 correct	 responses	 in	a	given	 time,	 compared	 to	age	normed	data.	 	Due	 to	 the	









The	 main	 findings	 of	 the	 current	 study	 are	 insufficient	 to	 support	 hypothesis	 one.	 No	
statistically	significant	differences	were	identified	in	between-group	comparisons	of	attention	
task	 performance.	 However,	 examination	 of	 effect	 sizes	 suggested	 reduced	 alerting	 and	
response	inhibition	in	the	COPD	group.	Furthermore,	for	a	small	subgroup,	these	difficulties	
met	criteria	for	clinical	impairment.	The	attention	performance	observed	in	this	stable	COPD	
cohort	 is	 somewhat	discordant	with	patterns	detected	on	similar	 tasks	 in	an	exacerbating	
	 74	
group	(Klein	et	al.,	2009).	However,	consistent	with	this	previous	investigation,	all	effect	sizes	
observed	 in	 the	 present	 study	 indicated	 some	 detrimental	 influence	 of	 COPD	 across	 all	
attention	 components	 investigated.	 This	 may	 suggest	 a	 graded	 detrimental	 impact	 of	
worsening	health	status,	which	differentially	 influences	subcomponents	of	attention.	Such	
patterns	 are	 supported	 by	 the	 findings	 of	 a	 prospective	 study	 (Dodd	 et	 al.,	 2013).		
Interestingly,	in	comparison	to	Klein	et	al.	(2009),	larger	negative	effect	sizes	were	observed	
across	 all	 measures	 of	 response	 inhibition.	 This	 pattern	 would	 suggest	 that	 stable	 COPD	
participants	may	experience	greater	difficulties	with	executive	attention	than	exacerbating	
counterparts.	 However,	 the	 observed	 effect	 sizes	 on	 ANT	 conflict	 relatively	 small	 in	 both	


















The	 findings	 of	 this	 study	 suggest	 that,	 for	 most	 stable	 COPD	 patients,	 any	 attention	
difficulties	experienced	are	unlikely	to	have	a	meaningful	impact	upon	everyday	functioning.	
Therefore,	routine	screening	of	attention	abilities	may	not	be	warranted	in	this	population.		
However,	 respiratory	 clinicians	 should	 be	 aware	 that	 a	 small	 sub-group	 are	 at	 risk	 of	




of	 understanding	during	 clinical	 conversations	may	highlight	 any	 information	 lost	 through	
concentration	 lapses.	 Difficulties	 with	 response	 inhibition	 may	 imply	 impaired	 impulse	










with	 indications	 that	 split-half	 reliabilities	 may	 be	 low	 for	 alerting	 and	 orienting	 effects,	
though	moderately	high	for	executive	control	(MacLeod	et	al.	2010).	Participants	in	this	study	










control	groups	means.	 It	 is	not	possible	to	determine	how	closely	these	scores	 fit	a	 larger	





















research	 should	 aim	 to	 address	 this	 issue	 by	 conducting	 prospective	 studies	 examining	
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	 1.1	 1.2	 1.3	 1.4	 1.5	 1.6	 1.7	 1.8	 1.9	 2.1	 2.2	 2.3	 Yin1	
Borson	 Y	 CS	 Y	 N	 Y	 CS	 Y	 N	 N	 +	 Y	 Y	 4	
Cleutjens	 Y	 Y	 Y	 N	 Y	 Y	 Y	 Y	 N	 ++	 Y	 Y	 7	
Dodd	 Y	 Y	 CS	 Y	 Y	 Y	 Y	 N	 N	 ++	 Y	 Y	 6	
Grant	 Y	 Y	 CS	 CS	 Y	 Y	 CS	 N	 N	 +	 CS	 Y	 4	
Incalzi	 Y	 Y	 Y	 N	 Y	 N	 Y	 N	 N	 +	 Y	 Y	 5	
Karakontaki	 Y	 CS	 Y	 N	 Y	 CS	 Y	 N	 N	 +	 Y	 Y	 4	
Liesker	 Y	 Y	 Y	 CS	 Y	 CS	 CS	 N	 N	 +	 Y	 Y	 4	
Ortapamuk	 Y	 CS	 CS	 CS	 Y	 Y	 Y	 N	 N	 +	 CS	 Y	 4	
Ryu	 Y	 CS	 Y	 N	 Y	 Y	 CS	 N	 N	 +	 CS	 Y	 4	
Spilling		 Y	 CS	 Y	 N	 Y	 Y	 CS	 N	 N	 +	 Y	 Y	 4	




































































































































































        
Centre Number:
Study Number:
Patient Identification Number for this trial:  
 
CONSENT FORM 
(For those with a diagnosis of Chronic Obstructive Pulmonary Disease)
Title of Project: “An Investigation of Attentional Functions in Stable COPD” 
Name of Researcher: Claire Alexander      Please initial box 
1. I confirm that I have read and understand the information sheet 
dated ...................... (version ............) for the above study. I have had the  
opportunity to consider the information, ask questions and have had these  
answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal  
rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected  
during the study, may be looked at by individuals from regulatory authorities  
or from the NHS Health Board, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.  
 
4. I consent to the researchers obtaining my most recent spirometry (lung  
function) results from my clinical care team 
 
 











Name of person taking consent Date    Signature 









If you would like your GP to be informed of your participation in the study please provide their 
contact details below.  
 










If you would like to receive a written summary report of the study findings, please provide details 






















        
Centre Number:
Study Number:




Title of Project: “An Investigation of Attentional Functions in Stable COPD” 
Name of Researcher: Claire Alexander      Please initial box 
6. I confirm that I have read and understand the information sheet 
dated ...................... (version ............) for the above study. I have had the  
opportunity to consider the information, ask questions and have had these  
answered satisfactorily.  
 
7. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal  
rights being affected.  
 










    





Name of person taking consent Date     Signature 










If you would like to receive a written summary report of the study findings, please provide details 

















        
“An Investigation of Attentional Functions in Stable COPD” 
 
Participant Information Sheet 
(For those with a diagnosis of Chronic Obstructive Pulmonary Disease) 
 
Invitation to take part in the research  
You are invited to take part in a research project. We are looking for adults aged 18 and 
over who have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) which is 
currently stable, have had no previous neurological conditions (e.g. Traumatic Brain 
Injury; Stroke), do not have severe sensory deficits (e.g. partial or complete blindness), 
and do not have other health conditions which significantly impact on their ability to 
engage with the tasks.  
 
Before deciding whether you want to participate or not it is important to understand why 
this research is being carried out and what taking part will involve. This information is 
outlined below. Please take the time to read this carefully and, if you wish, discuss it 
with others. If there is anything that is unclear or you would like more information on, 
please do not hesitate to ask. Take time to decide whether you would like to take part. 
Thank you for taking the time to read this information sheet.  
	
Who is conducting the research?  
The research project is being conducted by Claire Alexander (Trainee Clinical 
Psychologist), Dr Jim Law (Clinical Psychologist, NHS Highland), Dr Sue Turnbull and 
Professor Jonathan Evans from the Institute of Health and Well-being at the University 
of Glasgow. The study is being carried out to fulfil academic requirements for the 
University of Glasgow’s Doctorate in Clinical Psychology degree course.  
	
What is the purpose of the study?  
(i)Background 
Chronic Obstructive Pulmonary Disease (COPD) is predominantly a respiratory 
condition. However, many people with COPD also experience several other difficulties 
including high blood pressure, reduced mobility and anxiety. Difficulties vary a lot 
between people with COPD, and not everyone has difficulties in all these areas. In this 
project, we are particularly interested in how COPD might impact on brain functioning 




structure and function and this could affect how information is processed. Specifically, 
we are interested in a kind of brain function, attention. Attention is the brain’s way of 
processing information which we take in from the environment through our senses (for 
example, through seeing or hearing things). There are different types of attention, the 
most well-known types are: how we select information from the environment to attend 
to; and how long we can concentrate on something.  Previous work by other 
researchers has suggested that some people with COPD may have difficulties with 
some types of attention.  However, as this research is still in its infancy it is difficult to 
draw helpful conclusions from these studies. Several studies have also focussed on 
examining cognitive functioning while COPD patients are acutely unwell and staying in 
hospital. For this project, we wanted to examine COPD patients whose condition is 
currently stable as this represents most COPD patients. Problems with cognition during 
a stable phase of COPD may have important implications on patient’s quality of life.  If 
we find that attention is affected in stable COPD, this may therefore help us identify 
strategies that help people with COPD manage their treatment and daily activities. 
 
In this project we will measure different types of attention using a few different tasks. 
These will involve looking at a computer screen and responding to some visual stimuli, 
reading some words on a card and completing some sentences. Each of these tasks 
focus on particular components of attention based on established neuropsychological 
models of attention. In addition, we will investigate whether attention varies with disease 
severity and other important factors such as age or anxiety.  
(ii) Aims  
To investigate: (1) Whether individuals with stable COPD perform differently on 
attention tasks compared to people who do not have COPD; and (2) If there is a 
relationship between attention performance and other relevant factors such as disease 
severity. 
 
What does taking part involve?  
If you would like to take part, we will arrange a time convenient to you to come along 
and meet our researcher. Typically, the appointments would take place in an NHS 
building however if necessary it may be possible for the researcher to visit you at home.  
 
Participation involves completing some assessment measures which, in total, will take 
approximately 30-60 minutes. First, we will collect some demographic information such 
as age and any medication you might be taking. With your permission, we would also 
like to access information about your most recent lung function tests. We will use this 
information, to see if whether your lung functioning has any relationship with your 
performance on the tasks. We will also ask you to complete a short questionnaire about 
your mood.  
 
You will then be asked to complete three different tasks. One task will involve looking at 
a computer screen and responding to visual stimuli which is presented. A second task 
will involve reading information from a sheet of paper.  The last task will involve 
completing several sentences which will be read out to you.	With your permission, we 





What are the possible benefits of taking part?  
Research gives us the opportunity to improve our knowledge about various difficulties 
people with COPD may experience. Your participation in this study will help us increase 
our knowledge about cognition and attention in individuals with COPD and help us 
make improvements to treatment in the future.  
 
What are the possible risks or disadvantages of taking part?  
There are no significant risks or disadvantages of taking part in this study.  Although we 
do not predict that participating in this study will cause you any distress, if this were to 
happen we would help you access appropriate support.  
 
Do I have to take part?  
It is up to you whether you decide to take part in this study. If you decide you want to 
take part, you will be given a copy of this information sheet to keep and be asked to sign 
a consent form. Although you will be signing the consent form, please be aware that you 
are free to withdraw from the study at any time. A decision to withdraw from the study or 
not take part at all will have absolutely no impact on the standard of care you receive.  
 
Will my information be confidential?  
All information collected about you during the study will be kept strictly confidential. If 
any information about you was required to leave the hospital, your name and address 
will be removed so that you cannot be recognised from it.  
 
What happens to the information?  
Your personal information and identity will be kept strictly confidential and known only 
by the researchers. Information will be stored within a locked filing cabinet in the locked 
Psychology Department. All information will be held in accordance to the Data 
Protection Act (1998), meaning that it be stored securely and not shared with other 
people without your permission. If any findings from this study are published, your 
identity will be anonymised so you are not identifiable.  
 
What will happen to the results of the study?  
At the end of the study, the finished report will be submitted to the University of 
Glasgow. We hope that the findings will be published in a medical journal and through 
other sources to make sure the general public know what the study found. If you wish, 
you will be sent a written summary report of the findings. Your identity and personal 
information will not be reported or published following this study.  
 
Who is funding the research?  
The research is funded by the Doctorate in Clinical Psychology course at the University 
of Glasgow.  
 
Who has reviewed the study?  
The study has been reviewed by Glasgow University to make sure that it meets 




Committee of the NRES Committee West-Midlands South Birmingham has also 
reviewed this study to make sure that it meets standards outlined regarding ethical 
conduct.  
 
Who can I contact for further information?  
If you would like any additional information or have any questions, please do not 
hesitate to contact a member of the research team on the below contact details.  
Alternatively, if you would like to speak to someone independent to the study please use 
the below contact details. Please also use the independent contact information if you 
wish to raise a complaint. 
 
RESEARCH TEAM: 
Name Role Contact 
Claire Alexander Trainee Clinical 
Psychologist,  
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
 Inverness,  
IV3 8NP 
Tel: 01463 704683 
Dr Sue Turnbull and 
Professor Jon Evans 
Academic 
Supervisors, 
University of Glasgow 
University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, Glasgow,  
G12 0XH  
Tel: 0141 211 0607 
Dr Jim Law Field Supervisor, 
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
Inverness,  
IV3 8NP 
Tel: 01463 704683 
 
INDEPENDENT CONTACT:  







University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, Glasgow,  
G12 0XH  






        
“An Investigation of Attentional Functions in Stable COPD” 
 
Participant Information Sheet 
(For Healthy Volunteers) 
Invitation to take part in the research  
You are invited to take part in a research project. This project is investigating 
attention in people with Chronic Obstructive Pulmonary Disease (COPD), but in 
addition, we need a group of healthy people with whom to compare the participants 
with COPD. We are looking for adults aged 18 and over who do not have a diagnosis 
of Chronic Obstructive Pulmonary Disease (COPD) have had no previous 
neurological conditions (e.g. Traumatic Brain Injury; Stroke), do not have severe 
sensory deficits (e.g. partial or complete blindness), and do not have other health 
conditions which significantly impact on their ability to engage with the tasks.  
 
Before deciding whether you want to participate or not it is important to understand 
why this research is being carried out and what taking part will involve. This 
information is outlined below. Please take the time to read this carefully and, if you 
wish, discuss it with others. If there is anything that is unclear or you would like more 
information, please do not hesitate to ask. Take time to decide whether you would 
like to take part. Thank you for taking the time to read this information sheet.  
 
Who is conducting the research?  
The research project is being conducted by Claire Alexander (Trainee Clinical 
Psychologist), Dr Jim Law (Clinical Psychologist; NHS Highland), Dr Sue Turnbull 
and Professor Jonathan Evans from the Institute of Health and Well-being at the 
University of Glasgow. The study is being carried out to fulfil academic requirements 
for the University of Glasgow’s Doctorate in Clinical Psychology degree course.  
 
What is the purpose of the study?  
(i)Background 
Chronic Obstructive Pulmonary Disease (COPD) is predominantly a respiratory 
condition. However, many people with COPD also experience several other 
difficulties including high blood pressure, reduced mobility and anxiety. Difficulties 
vary a lot between people with COPD, and not everyone has difficulties in all these 
areas. In this project, we are particularly interested in how COPD might impact on 
brain functioning (cognition). There is emerging evidence that COPD may have 
some impact on the brain structure and function and this could affect how 
information is processed. Specifically, we are interested in a kind of brain function, 
attention. Attention is the brain’s way of processing information which we take in 
from the environment through our senses (for example, through seeing or hearing 




we select information from the environment to attend to; and how long we can 
concentrate on something.  Previous work by other researchers has suggested that 
some people with COPD may have difficulties with some types of attention.  
However, as this research is still in its infancy it is difficult to draw helpful conclusions 
from these studies. Several studies have also focussed on examining cognitive 
functioning while COPD patients are acutely unwell and staying in hospital. For this 
project, we wanted to examine COPD patients whose condition is currently stable as 
this represents most COPD patients. Problems with cognition during a stable phase 
of COPD may have important implications on patient’s quality of life.  If we find that 
attention is affected in stable COPD, this may therefore help us identify strategies 
that help people with COPD manage their treatment and daily activities.  
 
In this project, we will measure different types of attention using a few different tasks. 
These will involve looking at a computer screen and responding to some visual 
stimuli, reading some words on a card and completing some sentences. Each of 
these tasks focus on particular components of attention based on established 
neuropsychological models of attention. In addition, we will investigate whether 
attention varies with disease severity and other important factors such as age or 
anxiety.  
	
(ii) Aims  
To investigate: (1) Whether individuals with stable COPD perform differently on 
attention tasks compared to people who do not have COPD; and (2) If there is a 
relationship between attention performance and other relevant factors such as 
disease severity. 
 
What does taking part involve?  
If you would like to take part, we will arrange a time convenient to you to come along 
and meet our researcher. Typically, the appointments would take place in an NHS 
building however if necessary it may be possible for the researcher to visit you at 
home.  
 
Participation involves completing some assessment measures which, in total, will 
take approximately 30-60 minutes. First, we will collect some demographic 
information such as age and any medication you might be taking. We will also ask 
you to complete a short questionnaire about your mood.  
 
You will then be asked to complete three different tasks. One task will involve looking 
at a computer screen and responding to visual stimuli which is presented. A second 
task will involve reading information from a sheet of paper.  The last task will involve 
completing several sentences which will be read out to you.		
 
What are the possible benefits of taking part? 
Research gives us the opportunity to improve our knowledge about various 
difficulties people with COPD may experience. Your participation in this study will 
help us increase our knowledge about cognition and attention in individuals with 
COPD and help us make improvements to treatment in the future.  
 
What are the possible risks or disadvantages of taking part?  




we do not predict that participating in this study will cause you any distress, if this 
were to happen we would help you access appropriate support.  
 
Do I have to take part?  
It is up to you whether you decide to take part in this study. If you decide you want to 
take part, you will be given a copy of this information sheet to keep and be asked to 
sign a consent form. Although you will be signing the consent form, please be aware 
that you are free to withdraw from the study at any time. A decision to withdraw from 
the study or not take part at all will have absolutely no impact on the standard of care 
you receive.  
 
Will my information be confidential?  
All information collected about you during the study will be kept strictly confidential. If 
any information about you was required to leave the hospital, your name and 
address will be removed so that you cannot be recognised from it.  
 
What happens to the information?  
Your personal information and identity will be kept strictly confidential and known 
only by the researchers. Information will be stored within a locked filing cabinet in the 
locked Psychology Department. All information will be held in accordance to the Data 
Protection Act (1998), meaning that it be stored securely and not shared with other 
people without your permission. If any findings from this study are published, your 
identity will be anonymised so you are not identifiable.  
 
What will happen to the results of the study?  
At the end of the study, the finished report will be submitted to the University of 
Glasgow. We hope that the findings will be published in a medical journal and 
through other sources to make sure the general public know what the study found. If 
you wish, you will be sent a written summary report of the findings. Your identity and 
personal information will not be reported or published following this study.  
	
Who is funding the research?  
The research is funded by the Doctorate in Clinical Psychology course at the 
University of Glasgow.  
 
Who has reviewed the study?  
The study has been reviewed by Glasgow University to make sure that it meets 
standards outlined regarding scientific conduct. The Proportionate Review Sub-
Committee of the NRES Committee West-Midlands South Birmingham has also 
reviewed this study to make sure that it meets standards outlined regarding ethical 
conduct.  
 
Who can I contact for further information?  
If you would like any additional information or have any questions, please do not 
hesitate to contact a member of the research team on the below contact details. 
Alternatively, if you would like to speak to someone independent to the study please 
use the below contact details. Please also use the independent contact information if 









Claire Alexander Trainee Clinical 
Psychologist,  
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
Inverness,  
IV3 8NP 
Tel: 01463 704683 
Dr Sue Turnbull and 
Professor Jon Evans 
Academic Supervisors, 
University of Glasgow 
University of Glasgow  
1st Floor, Administration Building,  
Gartnavel Royal Hospital,  
1055 Great Western Road, 
Glasgow,  
G12 0XH  
Tel: 0141 211 0607 
Dr Jim Law Field Supervisor, 
NHS Highland 
Drumossie Unit,  
New Craigs Hospital, 
Inverness,  
IV3 8NP 
Tel: 01463 704683 
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MRC Dyspnoea Scale  
1  Breathless only with strenuous exercise  
2  Short of breath when hurrying on the level or up a slight hill.  
3  Slower than most people of the same age on a level surface or Have to stop when walking at my own pace on the level.  
4  Stop for breath walking 100 meters orAfter a walking few minutes at my 
own pace on the level  























































































































































GOLD	1-2	 ≤ 1 ≥	2	
C	 High	risk	
Less	symptoms	
GOLD	3-4	 ≥	2	 0	-1	
D	 High	risk	
More	symptoms	
GOLD	3-4	 ≥	2	 ≥	2	
	
